LX111 gene therapy for neovascular (wet) age-related macular degeneration
Official title: An Exploratory Clinical Study Evaluating LX111 Gene Therapy in Patients With Neovascular Age-related Macular Degeneration (nAMD)
Run by Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine · NCT07053358 · Data updated 2026-11-12
This will test a single eye injection of LX111 gene therapy in people 50 and older with active wet AMD to see if it is safe and helps maintain or improve vision.
Quick facts
| Phase | Early Phase 1 |
|---|---|
| Study type | Interventional |
| Ages | 50 Years and up |
| Sex | All |
| Enrollment | 10 (estimated) |
| Sponsor | Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine Academic / other |
| Locations | 1 site (Shanghai) |
| Status | Recruiting |
| Started | July 2, 2025 |
| Main results expected | November 23, 2026 |
| Study ends | December 30, 2029 |
| Registry record updated | March 10, 2026 |
| Trial ID | NCT07053358 on ClinicalTrials.gov |
Is this trial a fit for you?
✓Likely a good fit
Ideal candidates are adults aged 50 or older with active CNV due to neovascular AMD, best-corrected visual acuity between 5 and 63 ETDRS letters, a prior meaningful response to anti-VEGF therapy, and willingness to attend follow-up visits and use effective contraception if fertile.
✕Probably not a fit
Patients with CNV or macular edema from other diseases, serious ocular conditions that limit visual improvement (like retinal detachment, uveitis, uncontrolled glaucoma), recent major cardiovascular events, or uncontrolled hypertension are unlikely to benefit from this protocol.
A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.
What this trial studies
This early Phase 1 interventional study gives a single unilateral intravitreal injection of LX111 to adults aged 50 and older with active choroidal neovascularization from neovascular AMD. Participants must have had at least two anti-VEGF injections in the prior six months and shown a meaningful response before enrollment. The trial will closely monitor safety outcomes and measures of visual acuity over scheduled follow-up visits. Results will inform whether LX111 can provide durable control of disease activity with acceptable tolerability.
Why it matters
Potential benefit: If successful, LX111 could reduce the need for frequent anti-VEGF injections and provide longer-lasting control of wet AMD, helping preserve vision.
How similar studies have gone: Other intraocular gene therapy programs for wet AMD (for example AAV-based approaches) have shown early promise in Phase 1/2 studies but remain experimental and not yet established as standard care.
Who can join: the full rules
Show full inclusion / exclusion criteria
Inclusion Criteria: 1. Willing to sign the informed consent, and willing to attend follow-up visits. 2. Age ≥ 50 3. Diagnosis of active CNV secondary to neovascular AMD 4. BCVA ETDRS letters between 5 and 63 5. Subjects must have received a minimum of 2 injections within 6 months prior to screening and demonstrated a meaningful response to anti-VEGF therapy 6. Male subjects whose partner is a fertile female or female subjects who are fertile, agree to take effective contraceptive measures from the screening period until the last follow-up. Exclusion Criteria: 1. CNV or macular edema in the study eye secondary to diseases other than nAMD 2. Retinal detachment, uveitis, uncontrolled glaucoma in the study eye, or any condition preventing visual acuity improvement 3. Acute coronary syndrome, myocardial infarction or coronary artery revascularization, CVA, TIA in the last 6 months 4. Uncontrolled hypertension defined as average SBP ≥160 mmHg or an average DBP ≥100 mmHg 5. Uncontrolled diabetes defined as HbA1c \>8.0% within 28 days prior to screening
Where it's running
-
Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine
Shanghai, China Recruiting
Similar studies
Other studies for the same condition or treatment. Recruiting studies are listed first.
-
ABP 938 8 mg vs EYLEA® HD (aflibercept) in neovascular AMD
This trial tests whether ABP 938 8 mg works as well as aflibercept 8 mg in people with neovascular AMD.
-
PRL3-zumab for neovascular (wet) age-related macular degeneration
This trial tests whether three intravenous doses of PRL3-zumab given every two weeks can help people with neovascular (wet) age-related macular degeneration who have not responded to at least two standard intravitreal treatments.
-
IBI302 treatment for neovascular age-related macular degeneration
This trial will try intravitreal 8 mg IBI302 injections to see if they help people aged 50 and older with active neovascular (wet) AMD.
-
Surabgene Lomparvovec to reduce injections and preserve vision in adults with wet AMD
This study will test whether a single subretinal dose of Surabgene Lomparvovec can reduce the need for repeated eye injections and help preserve vision in adults 50 and older with previously treated neovascular (wet) AMD compared with standard ranibizumab care.
-
Effects of Faricimab on kidney function in diabetic patients
This study is testing if a new eye injection called Faricimab can help improve kidney function in people with diabetes compared to a standard treatment.
-
Port Delivery System with ranibizumab refilled every 36 weeks for neovascular (wet) AMD
This trial tests whether a refillable eye implant that delivers ranibizumab every 36 weeks works and is safe for people with recent neovascular (wet) age-related macular degeneration who responded to prior anti-VEGF injections.
How to take part
- Review the eligibility criteria above with your treating physician.
- Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
- Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.